Warren S J P, Arteaga L A, Rivitti E A, Aoki V, Hans-Filho G, Qaqish B F, Lin M S, Giudice G J, Diaz L A
Department of Dermatology, University of North Carolina at Chapel Hill, North Carolina 27599, USA.
J Invest Dermatol. 2003 Jan;120(1):104-8. doi: 10.1046/j.1523-1747.2003.12017.x.
Endemic pemphigus foliaceus, like the sporadic form seen in the developed world, is mediated by IgG antibodies to desmoglein-1. We studied an endemic focus in Limao Verde, Brazil, where disease prevalence is 3.4%. We previously detected IgG antibodies to desmoglein-1 in 97% of patients, but also in 55% of normal subjects in the endemic focus, with progressively lower levels in normal subjects in surrounding areas. An environmental trigger is hypothesized to explain these and other findings. In this study we sought to determine if patients and enzyme-linked-immunosorbent-assay-positive normal subjects in Limao Verde differ in IgG subclass response to desmoglein-1. We developed a sensitive and specific subclass enzyme-linked immunosorbent assay using recombinant desmoglein-1 and standardized the assay to enable comparability between the four subclasses. We found that normal subjects have an IgG1 and IgG4 response, whereas patients have similar levels of IgG1 but a mean 19.3-fold higher IgG4 response. Patients in remission have a weak IgG4 response, and a 74.3-fold higher IgG4 response is associated with active disease. Finally, in five patients in whom we had blood samples from both before and after the onset of clinical disease, a mean 103.08-fold rise in IgG4 was associated with onset of clinical disease, but only a mean 3.45-fold rise in IgG1. These results suggest that the early antibody response in normal subjects living in the endemic area and in patients before the onset of clinical disease is mainly IgG1. Acquisition of an IgG4 response is a key step in the development of clinical disease.
地方性落叶型天疱疮,与在发达国家所见的散发性形式一样,是由针对桥粒芯糖蛋白-1的IgG抗体介导的。我们研究了巴西利毛奥韦尔德的一个地方性发病区,那里的疾病患病率为3.4%。我们之前在97%的患者中检测到了针对桥粒芯糖蛋白-1的IgG抗体,但在该地方性发病区55%的正常受试者中也检测到了,周边地区正常受试者中的抗体水平逐渐降低。据推测,有一个环境触发因素可以解释这些及其他发现。在本研究中,我们试图确定利毛奥韦尔德的患者以及酶联免疫吸附测定呈阳性的正常受试者在针对桥粒芯糖蛋白-1的IgG亚类反应方面是否存在差异。我们利用重组桥粒芯糖蛋白-1开发了一种灵敏且特异的亚类酶联免疫吸附测定,并对该测定进行了标准化,以使四个亚类之间具有可比性。我们发现,正常受试者有IgG1和IgG4反应,而患者的IgG1水平相似,但IgG4反应平均高19.3倍。缓解期患者的IgG4反应较弱,而IgG4反应高74.3倍与疾病活动相关。最后,在5例临床疾病发作前后均有血样的患者中,IgG4平均升高103.08倍与临床疾病发作相关,但IgG1仅平均升高3.45倍。这些结果表明,生活在地方性发病区的正常受试者以及临床疾病发作前患者的早期抗体反应主要是IgG1。获得IgG4反应是临床疾病发生发展的关键步骤。